Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology leader developing novel immunotherapies and vaccines for cancer and infectious diseases. This dedicated news hub provides investors and researchers with essential updates on the company’s pioneering work in neoantigen-targeting platforms and self-amplifying mRNA technology.
Access real-time announcements including clinical trial results, regulatory milestones, and strategic collaborations. Our curated collection features:
• Clinical development updates for GRANITE and SLATE vaccine programs
• Technology innovations in AI-driven EDGE platform and samRNA vectors
• Partnership announcements with leading research institutions
• Peer-reviewed data publications and conference presentations
Bookmark this page for streamlined tracking of Gritstone bio’s progress in advancing personalized cancer vaccines and next-generation infectious disease solutions. All content is sourced directly from company filings and verified industry channels.
Gritstone bio, Inc. (Nasdaq: GRTS) appointed Stephen Webster, a finance executive with 30 years of experience, to its Board of Directors. Webster's expertise in raising capital and business development will be important as the company prepares for Phase 2 GRANITE data and potential growth. Steve Krognes will not stand for re-election at the 2024 Annual Meeting.